Chemed Corporation (NYSE:CHE) Stock Now Rated "Hold" by Sell-Side Analysts

Key Points

• Analyst consensus is “Hold”: Five of seven covering firms rate Chemed neutral, while two rate it a buy. The average 12-month price target is $554.60, with targets ranging from recent $548–$650 levels.
• Chemed reported quarterly earnings of $6.06 per share, beating estimates of $5.60, while revenue rose 8.8% year over year to $673.25 million. The company issued fiscal 2026 EPS guidance of $25.00–$25.75.
• The company raised its quarterly dividend from $0.60 to $0.70 per share, although insiders sold 9,190 shares worth $4.83 million over the past 90 days. Institutional investors own approximately 95.85% of Chemed’s stock.

Chemed Corporation (NYSE:CHE - Get Free Report) has received an average rating of "Hold" from the seven research firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $554.60.

CHE has been the subject of a number of analyst reports. Weiss Ratings raised shares of Chemed from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday. Royal Bank Of Canada upped their target price on shares of Chemed from $436.00 to $548.00 and gave the company a "sector perform" rating in a research note on Thursday, July 30th. Wall Street Zen raised shares of Chemed from a "buy" rating to a "strong-buy" rating in a research report on Saturday. UBS Group assumed coverage on shares of Chemed in a research note on Friday, September 25th. They set a "buy" rating and a $650.00 price target for the company. Finally, Oppenheimer lifted their price objective on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a report on Friday, July 31st.

Insider Buying and Selling

In related news, EVP Spencer Lee sold 1,000 shares of the firm's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the transaction, the executive vice president owned 13,912 shares in the company, valued at $7,526,948.48. This trade represents a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin McNamara sold 2,000 shares of the business's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $539.51, for a total value of $1,079,020.00. Following the completion of the sale, the chief executive officer directly owned 70,418 shares in the company, valued at approximately $37,991,215.18. This represents a 2.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 9,190 shares of company stock worth $4,833,160 in the last 90 days. 3.33% of the stock is owned by company insiders.

Institutional Investors Weigh In On Chemed

Several institutional investors and hedge funds have recently made changes to their positions in CHE. BlackRock Inc. acquired a new stake in shares of Chemed in the second quarter valued at $691,290,000. First Trust Advisors LP raised its holdings in shares of Chemed by 24.7% in the first quarter. First Trust Advisors LP now owns 236,392 shares of the company's stock valued at $89,295,000 after buying an additional 46,791 shares during the last quarter. Copeland Capital Management LLC lifted its position in Chemed by 7.6% during the 1st quarter. Copeland Capital Management LLC now owns 147,957 shares of the company's stock worth $55,889,000 after buying an additional 10,406 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Chemed by 7.9% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 107,215 shares of the company's stock worth $40,481,000 after buying an additional 7,807 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Chemed during the 2nd quarter worth about $48,255,000. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Performance

Shares of NYSE CHE opened at $500.46 on Tuesday. The firm has a market capitalization of $6.54 billion, a price-to-earnings ratio of 25.14, a PEG ratio of 2.01 and a beta of 0.51. Chemed has a one year low of $365.20 and a one year high of $557.00. The business has a fifty day simple moving average of $520.47 and a 200 day simple moving average of $467.89. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17.

Chemed (NYSE:CHE - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping analysts' consensus estimates of $5.60 by $0.46. The firm had revenue of $673.25 million for the quarter, compared to the consensus estimate of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business's revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Sell-side analysts expect that Chemed will post 23.55 EPS for the current year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 17th. This is a boost from Chemed's previous quarterly dividend of $0.60. Chemed's payout ratio is currently 14.06%.

Chemed Company Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.